Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease with a wide range of clinical manifestations. It is most often caused by deficiency of steroid 21-hydroxylase, reflecting any of a wide range of mutations in the 21-hydroxylase (CYP21) gene. A major challenge in molecular diagnostics of CAH is the high homology between the CYP21 gene and the CYP21P pseudogene and the phenomenon of apparent gene conversion, which inactivates the functional gene. In this study we devised an improved stepwise diagnostic procedure involving nonradioactive Southern blotting and direct DNA sequencing. This strategy led to a successful elucidation of the molecular cause of the disease in 181 out of 182 unrelated alleles in a total of 91 clinically and biochemically characterized patients. We were able to identify all classical known disease-causing mutations of the 21-hydroxylase gene and a novel nonsense mutation (bp 670, A→C, Y97X). Our method also allows the reliable, secure diagnosis of the heterozygous configuration and may therefore be used for pre-, peri-, and postnatal diagnosis of CAH, even when informative data of the index patient are lacking. Furthermore, it can be used to confirm the diagnosis of CAH in newborns detected in 17-hydroxyprogesterone screening programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Dupont, J., Zhu, D., Serrat, J., Buegeleisen, M., Tusie-Luna, M. T., Lesser, M., New, M. I., & White, P. C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115897 · Cited by 572 · cited 3×
“The maximum sensitivity in CAH mutation detection reported thus far in other studies ranges from 90% (26) to 95% (27).”
BackgroundResultStructure of human steroid 21-hydroxylase genes.
White, P. C., New, M. I., & Dupont, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5111 · Cited by 569
Higashi, Y., Yoshioka, H., Yamane, M., Gotoh, O., & Fujii-Kuriyama, Y. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2841 · Cited by 555 · cited 1×
“b 59 site of 21-hydroxylase primers according to Higashi et al. ( 7 ) ;5 9 site of”
MethodHigh frequency of nonclassical steroid 21-hydroxylase deficiency
SPEISER, P. W., DUPONT, B. O., RUBINSTEIN, P., PIAZZA, A., KASTELAN, A., & NEW, M. I. (1986) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198604000-00017 · Cited by 523
Wedell, A. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1145 · Cited by 370
Characterization of frequent deletions causing steroid 21-hydroxylase deficiency
White, P. C., Vitek, A., Dupont, B., & New, M. I. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4436 · Cited by 229
Tusie-Luna, M.-T., Speiser, P. W., Dumic, M., New, M. I., & White, P. C. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-5-685 · Cited by 183 · cited 1×
“Therefore, allele-specific amplification strategies as well as pre-PCR TaqI digestion of genomic DNA have been developed to avoid the amplification of the CYP21P gene (10, 15, 16).”
MethodWedell, A., Ritzén, E. M., Haglund-Stengler, B., & Luthman, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7232 · Cited by 150
Mutations in steroid 21-hydroxylase (CYP21)
White, P. C., Tusie-Luna, M.-T., New, M. I., & Speiser, P. W. (1994) · Human Mutation · doi:10.1002/humu.1380030408 · Cited by 129 · cited 7×
“We were able to identify all classical known, disease-causing mutations of the 21-hydroxylase gene in a frequency similar to other studies (2, 27, 29, 30) Furthermore, it was possible to detect a novel mutation located in the genomic sequence (Y97X).”
BackgroundResultInfluentialHÖLLER, W., SCHOLZ, S., KNORR, D., BIDLINGMAIER, F., KELLER, E., & ALBERT, E. D. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-4-757 · Cited by 41 · cited 2×
“Furthermore, associations of disease-causing alleles to certain HLA alleles have been observed (4).”
Background
Cited by
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Mighell, A. J., Smith, N. R., Robinson, P. A., & Markham, A. F. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01199-6 · Cited by 407
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
“A 45 5 0 50 28 22 I2 G/conva 2.58 4 — — 4 2 2 I2 G/del 7.74 10 2 — 12 7 5 I2 G/141 delTb 0.65 1 — — 1 — 1 I2 G/I2Gc 1.90 18 2 — 20 13 7 I2 G/Y97Xd 0.65 1 — — 1 — 1 I2 G/E3 D8bp 1.94 2 1 — 3 2 1 I2 G/E6 cluster 0.65 1 — — 1 — 1 I2 G/F306 1t 0.65 1 — — 1 1 — I2 G/Q318X 2.58 4 — — 4 3 1 I2 G/R356W 1.94 3 — — 3 — 3 B 13 3…”
BackgroundMethodInfluentialSelf-citationGenetics of congenital adrenal hyperplasia
Krone, N., & Arlt, W. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.014 · Cited by 312
Self-citationNewborn screening for congenital adrenal hyperplasia
Therrell, B. L. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(08)70017-3 · Cited by 221
Metadata
- Authors
- Krone, N., Roscher, A. A., Schwarz, H. P., & Braun, A.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-10-01
- Volume
- 44
- Issue
- 10
- Pages
- 2075-2082
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2113896540
- Cited by
- 47
- References
- 10
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. https://app.cochat.ai/papers/10.1093/clinchem/44.10.2075
- The paper
- Krone, N., Roscher, A. A., Schwarz, H. P., & Braun, A. (1998). Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. Clinical Chemistry. https://doi.org/10.1093/clinchem/44.10.2075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.